Erez Chimovits is a Managing Director at OrbiMed and Chairman of Nucleix. Erez has 14 years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed Erez was the CEO of NasVax (TASE:NSVX). NasVax acquired Protea and struck agreements with GlaxoSmithKline and Novartis. Previously, Erez spent more than seven years with Compugen (Nasdaq:CGEN), as President, Compugen USA Inc. and Executive VP, Commercial Operations. At Compugen, he had responsibility for more than 100 people and led multiple transactions including J&J, Novartis, Teva, Abbott, Medarex and others. Erez earned his M.B.A., M.Sc. in Microbiology and his B.Sc. from Tel Aviv University.
Dr. Dreismann, is a seasoned executive with more than 30 years of experience in the health care industry, and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique, one of the most ubiquitous technologies in molecular biology and genetics research today. He had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO, Roche Molecular Systems, Head of Global Business Development, Roche Diagnostics and Member of Roche’s Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Munster) in Germany.
With 17 years diverse industry experience, Eli is currently Managing Director – Healthcare for Aurum Ventures MKI. Prior to his current position, he served as the Chief Business Officer of FutuRx, the drug development incubator established by J&J, Orbimed and Takeda. Prior to that, Eli served for 10 years as the COO of Aposense Ltd., a drug development and molecular imaging company (TASE: APOS), with responsibilities for business development, operations and finance. Before joining Aposense, he served as a Senior Business Development manager at GE Healthcare Europe (based in France), doing healthcare M&A across Europe. Eli holds an MBA from the Ecole des Ponts, in Paris, and a PhD in Chemistry (nanotechnology) from the Weizmann Institute of Science.
Yoav Chelouche is a leading figure in Israeli high-tech and since mid- 2012 serves as co-chairman of the Israeli Advanced Technology Industries (IATI) organization together with Dr. Benny Zeevi. Since 2001, Mr. Chelouche has been a managing partner of Aviv Venture Capital involved in all aspects of managing the firm formulating strategy, capital raising and evaluating and selecting portfolio companies. He serves as director and observer on the boards of several of the firms portfolio companies. Chelouche is currently a board member of Check Point Software Technologies and in the past served as Chairman of the Board of a number of public companies listed on various securities exchanges, including: Dmatek (LSE), Rosetta Genomics (NASDAQ) and Rosetta Green (TASE). During the years 1996-2001 he served as President and CEO of Scitex Corporation and successfully led the rehabilitation of the company’s core business and the buildup of its activities in digital printing. Prior to being appointed president and CEO of the company, Chelouche served in several VP positions at Scitex and was responsible for formulating and implementing the strategy to specialize in digital printing and for managing the company’s operations in Japan. In 2010 he was awarded the distinction of being one of the fifty graduates who have changed the world by INSEAD, the French university at which he studied Business Administration.
Dr. Opher Shapira is the CEO of Nucleix. Opher is an experienced entrepreneur and manager with close to 20 years of experience in the medical industry. Opher was the founder, President and CEO of BioView Ltd. (Public TASE). Opher has a PhD in Physics from Yale University and a B.Sc. in Physics and Computer Sciences from Tel Aviv University.